Antifungal peptides from scleroderma texense

Details Antifungal peptides from scleroderma texense Antifungal peptides from scleroderma texense

1999-05-18

2001-04-24

Davenport, Avis M. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C530S300000, C530S326000

Reexamination Certificate

active

06221844

ABSTRACT:

The invention relates to novel peptides, namely texenomycins, from Scleroderma texense, in particular the peptides texenomycin A and B, a process for their preparation and their use as pharmaceuticals, in particular as antimycotics.
The texenomycins according to the present invention are distinguished in particular by the amino acid sequence I (SEQ ID NO: 1).
in which
FS is an oxo fatty acid radical,
Aib is aminoisobutyric acid and
Arg-ol=argininol.
The fatty acid radical consists of 3 to 20, preferably of 8 to 15, carbon atoms.
The oxo group of the fatty acid radical is preferably located in the 3-position.
Compounds which correspond to the texenomycins have not been described in the literature to date. Structurally comparable compounds, such as the recently described trichosporins (cf. T. Fujita et al., J. Antibiotics (1988), 41, 814) differ, however, solely by the lower number of Aib radicals and by the amino acid sequence.
The fatty acid radical of the peptides according to the invention particularly preferably has the constitutional formula II
where the preferred peptides texenomycin A and B differ from one another only by the configuration (R or S configuration) of the carbon atom arranged between the two carbonyl groups or by the spatial arrangement of the methyl group substituting this atom.
The preferred texenomycins A and B are formed by the fungus Scleroderma texense, preferably Scleroderma texense DSM 10601, and are characterized in that they have the empirical formula C
97
H
170
N
24
O
23
(texenomycin A) or C97H
170
N
24
O
23
(texenomycin B), have a UV maximum at 280 nm (measured in methanol) and have the melting points of 215-216° C. (texenomycin A) or 209° C. (texenomycin B).
The subject of the present invention furthermore includes the processes for the preparation of the compounds mentioned. A process for the preparation of the compounds mentioned comprises culturing the microorganism Scleroderma texense, preferably Scleroderma texense DSM 10601, in an aqueous medium and then isolating and purifying the target compounds.
The microorganism Scleroderma texense DSM 10601 has been deposited on Mar. 20, 1996 in the Deutsche Sammiung von Mikrooganismen und Zellkulturen GmbH [German Collection of Microorganisms and Cell Cultures, (DSMZ)]; Mascheroder Weg 1b, D-38124 Brunswick according to the rules of the Budapest Convention.
Instead of the strain DSM 10601, its mutants and variants can also be employed insofar as they can synthesize peptides of the formula I. Such mutants can be produced in a manner known per se by physical means, for example irradiation, such as with ultraviolet or X-rays, or chemical mutagens, such as, for example, ethyl methanesulfonate (EMS), 2-hydroxy-4-methoxybenzophenone (MOB) or N-methyl-N′-nitro-N-nitrosoguanidine (MNNG).
The present invention accordingly also relates to Scleroderma texense DSM 10601 and its mutants and variants.
The fermentation conditions described below apply to Scleroderma texense and the deposited isolate DSM 10601. The fermentation can be carried out on the laboratory scale (milliliter and liter scale) or on the industrial scale (cubic meter scale).
In a nutrient solution which contains a carbon source and a nitrogen source as well as the customary inorganic salts, S. texense, in particular S. texense DSM 10601, produces the peptides of the formula I.
Suitable preferred carbon sources for aerobic fermentation are assimilable carbohydrates and sugar alcohols, such as glucose, lactose or D-mannitol, and carbohydrate-containing natural products, such as, for example, malt extract. Suitable nitrogen-containing nutrients are: amino acids, peptides and proteins and also their degradation products, such as peptones or tryptones, furthermore meat extracts, ground seeds, for example of corn, wheat, beans, soy or of the cotton plant, distillation residues from alcohol production, meat meals or yeast extracts, but also ammonium salts and nitrates. Inorganic salts which the nutrient solution can contain are, for example, chlorides, carbonates, sulfates or phosphates of the alkali metals or alkaline earth metals, iron, zinc, cobalt and manganese.
The formation of the compound of the formula I using S. texense, preferably DSM 10601, proceeds particularly well in a nutrient solution which contains 0.05 to 5%, preferably 0.1 to 2%, of casein peptone, 0.5 to 7%, preferably 0.1 to 2%, of meat peptone, 0.1 to 5%, preferably 0.5 to 3%, of glucose, and also 0.1 to 5%, preferably 0.5 to 3% of maltose, in each case based on the weight of the total nutrient solution.
Culturing is carried out aerobically, i.e., for example, under submerse conditions with shaking or stirring or in fermenters, if appropriate with introduction of air or oxygen. It is carried out in a temperature range from 15 to 30° C., in particular from 23 to 28° C. The pH is from pH 1 to 7, advantageously from pH 2.5 to 4.5. The fungus is cultured under these conditions over a period of 100 to 300 hours, preferably 120 to 168 hours.
Culturing is advantageously carried out in several stages, i.e. one or more precultures are first prepared in liquid nutrient medium, which are then transferred into the actual production medium, the main culture, for example in the volume ratio 1:10. The preculture is obtained, for example, by transferring mycelium into a nutrient solution and allowing it to grow for approximately 100 to 200 hours, preferably 120 to 168 hours. The mycelium can be obtained, for example, by allowing the strain to grow for 7 to 40 days, preferably 10 to 20 days, on a solid or liquid nutrient medium, for example yeast-malt agar or potato-dextrose agar.
The course of the fermentation can in each case be monitored by means of the pH of the culture or the mycelium volume and also by chromatographic methods, such as, for example, thin-layer chromatography or high-pressure liquid chromatography (HPLC).
The texenomycins can occur both in the mycelium and in the culture filtrate, usually the main amount is found in the cell mass. It is therefore expedient to separate this from the filtrate by filtration or centrifugation. The filtrate is lyophilized and the lyophilizate is extracted with a solvent such as methanol, acetonitrile or 1-butanol. Texenomycins can be extracted from the mycelium in the same manner. The extractions can be carried out over a wide pH range; a range of pH 3.0-7.5 is expedient.
Another method of isolation is solution partition in a manner known per se.
Another method of purification is chromatography on adsorption resins such as, for example, on Diaion® HP-20 (Mitsubishi Casei Corp., Tokyo), on Amberlite® XAD 7 (Rohm and Haas, USA), on Amberchrom® CG (Toso Haas, Philadelphia, USA) or on similar supports. Numerous reversed-phase supports are moreover suitable, e.g. RP-18, such as are generally used in high-pressure liquid chromatography (HPLC). A further possibility of purification for the texenomycins consists in the use of so-called straight-phase supports such as, for example, silica gel or alumina. Many solvents such as, for example, chloroform/methanol/glacial acetic acid mixtures are suitable for elution.
An alternative process for the isolation of the texenomycins is the use of so-called molecular sieves, such as, for example, Fractogel® TSK HW-40, Sephadex® LH-20. It is moreover also possible to obtain the texenomycins from enriched material by crystallization. For example, organic solvents and their mixtures, anhydrous or with addition of water, are suitable for this purpose. Additions of acids, such as, for example, trifluoroacetic acid, sulfuric acid, hydrochloric acid, formic acid or others, can likewise be advantageous.
It was found that the texenomycins inhibit the growth of various human-pathogenic fungi, e.g.
Candida albicans
with an MIC (minimum inhibitory concentration) of 0.24 &mgr;g/mL (Tex. A) or 0.49 &mgr;g/mL (Tex. B).
The substances according to the invention are suitable for the therapy and prophylaxis of fungal infections.
The present invention therefore also relates to a peptide of the formula I f

Affiliated with

Also associated with

Rating

Antifungal peptides from scleroderma texense does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antifungal peptides from scleroderma texense, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antifungal peptides from scleroderma texense will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2506406